Allogene Therapeutics (ALLO) Company Overview

Description:

Allogene Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company's focus is on immuno-oncology - developing allogeneic T-cell therapy with gene editing for cancer treatment. Founded in 2017, the company's headquarters are located in South San Francisco, California. The company is developing T-cell candidates designed to target and destroy cancer cells. These T-cells are allogeneic, meaning they are obtained from healthy donors for potential use in any patient, rather than from an individual patient for that patient's use, as is the case with autologous T-cells. Allogene believes that this key difference will ultimately allow for faster, more reliable, and on a larger scale, providing accessible treatment to a greater number of patients.